Familial hypercholesterolaemia is a relatively frequently
occurring disease that is strongly associated with vascular
disease. Current treatment with cholesterol-lowering
agents is partly effective but shows variable responses
between patients with familial hypercholesterolaemia.
Recently, new cholesterol-lowering drugs have been
developed. Here we describe the most promising of these
new agents for which results from phase 2 or phase 3 trials are available. We will discuss the data regarding
lipid-lowering potential and safety issues and speculate
about the potential reductions of the residual risk of statin-treated FH patients.